Xuzhou Thingdi Pharmaceutical Co., Ltd.

Phase IIa evaluates the efficacy, safety, and pharmacokinetic characteristics of 3D1002 50, 100, and 150 mg po q12h in the treatment of patients with moderate to severe cancer pain. Phase IIb compares the efficacy and safety of 3D1002 combined with oxycodone hydrochloride extended-release tablets versus oxycodone hydrochloride extended-release tablets alone in the treatment of patients with moderate to severe cancer pain by studying the total pain intensity difference index 14 days after the first drug treatment, and evaluates the drug interaction between 3D1002 and oxycodone hydrochloride extended-release tablets.

Primary objective: To evaluate the effect of 3D-229 combined with PAC (3D-229+PAC) vs. placebo and PAC (placebo+PAC) on progression-free survival (PFS) in subjects with platinum-resistant recurrent ovarian cancer based on RECIST 1.1 criteria Secondary objective: To evaluate the effect of 3D-229+PAC vs. placebo+PAC on overall survival (OS)

Single-dose escalation (SAD) cohort Evaluate the safety and tolerability of a single dose of 3D-229 in healthy subjects. Repeated-dose (RD) cohort Evaluate the safety and tolerability of repeated doses of 3D-229 RD in healthy subjects.